TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Wang, Shumin ^a   Xiao, Xue ^a   Zhou, Xiaoying ^a   Huang, Tingting ^a   Du, Chunping ^a   Yu, Nana ^a   Mo, Yingxi ^b   Lin, Longde ^a   Zhang, Jinyan ^a   Ma, Ning ^c   Murata, Mariko ^b   Huang, Guangwu ^a   Zhang, Zhe ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CPG OLIGODEOXYNUCLEOTIDE; GENOMIC DNA; MESSENGER RNA; PLACENTA PROTEIN 5; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DRUG DERIVATIVE; GLYCOPROTEIN; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

AGE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENDER; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; NASOPHARYNX CARCINOMA; PRIMARY TUMOR; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE; CARCINOMA; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR; TUMOR CELL LINE;

AZACITIDINE; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; EPIGENESIS, GENETIC; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLYCOPROTEINS; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 78049518977     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-617     Document Type: Article

References (34)

1. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007, 9(12):1-24. 10.1017/S1462399407000312, 17477889.
2. Sun D, et al. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 2007, 43(1):82-7. 10.1016/j.oraloncology.2006.01.007, 16807071.
3. Zhang Z, et al. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 2007, 120(1):32-8. 10.1002/ijc.22185, 17013896.
4. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12(6):451-62. 10.1016/S1044579X02000883, 12450731.
5. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2006, 94(2):179-83. 10.1038/sj.bjc.6602918, 2361113, 16404435.
6. Miyagi Y, et al. Assignment of the human PP5/TFPI-2 gene to 7q22 by FISH and PCR-based human/rodent cell hybrid mapping panel analysis. Genomics 1996, 35(1):267-8. 10.1006/geno.1996.0353, 8661135.
7. Rao CN, et al. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 1995, 317(1):311-4. 10.1006/abbi.1995.1168, 7872799.
8. Sprecher CA, et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994, 91(8):3353-7. 10.1073/pnas.91.8.3353, 43575, 8159751.
9. Wong CM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007, 45(5):1129-38. 10.1002/hep.21578, 17464989.
10. Wojtukiewicz MZ, et al. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003, 90(1):140-6.
11. Miyagi Y, et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem 1994, 116(5):939-42.
12. Ran Y, et al. A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. Hum Gene Ther 2009, 20(1):41-9. 10.1089/hum.2008.129, 20377370.
13. Wahlstrom T, Bohn H, Seppala M. Immunohistochemical demonstration of placental protein 5 (PP5) -like material in the seminal vesicle and the ampullar part of vas deferens. Life Sci 1982, 31(24):2723-5. 10.1016/0024-3205(82)90717-2, 6759834.
14. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001, 20(3-4):173-93. 10.1023/A:1015575125780, 12085961.
15. Sell SM, et al. Minimal interval defined on 7q in uterine leiomyoma. Cancer Genet Cytogenet 2005, 157(1):67-9. 10.1016/j.cancergencyto.2004.06.007, 15676150.
16. Kempaiah P, Chand HS, Kisiel W. Identification of a human TFPI-2 splice variant that is upregulated in human tumor tissues. Mol Cancer 2007, 6:20. 10.1186/1476-4598-6-20, 1828166, 17352822.
17. Hube F, et al. Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 2003, 109(4):207-15. 10.1016/S0049-3848(03)00147-6, 12757776.
18. Konduri SD, et al. Physiological and chemical inducers of tissue factor pathway inhibitor-2 in human glioma cells. Int J Oncol 2003, 22(6):1277-83.
19. Ribarska T, et al. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics 2010, 7(2):51-60.
20. Hibi K, et al. Methylation of TFPI2 gene is frequently detected in advanced well-differentiated colorectal cancer. Anticancer Res 2010, 30(4):1205-7.
21. Sato N, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005, 24(5):850-8. 10.1038/sj.onc.1208050, 15592528.
22. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996, 24(24):5064-6. 10.1093/nar/24.24.5064, 146326, 9016686.
23. Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994, 84(12):4384-5.
24. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007, 33(7):653-9. 10.1055/s-2007-991532, 18000791.
25. Jiang P, et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Sci 2006, 97(11):1267-73. 10.1111/j.1349-7006.2006.00308.x, 16965396.
26. Nobeyama Y, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007, 121(2):301-7. 10.1002/ijc.22637, 17372906.
27. Rollin J, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005, 92(4):775-83. 10.1038/sj.bjc.6602298, 2361876, 15685245.
28. Konduri SD, et al. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001, 18(1):127-31.
29. Konduri SD, et al. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene 2003, 22(29):4509-16. 10.1038/sj.onc.1206695, 12881707.
30. Rao CN, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001, 7(3):570-6.
31. Horikawa T, et al. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000, 89(4):715-23. 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9, 10951332.
32. Wong TS, et al. Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2004, 30(5):560-4. 10.1016/j.ejso.2004.02.007, 15135487.
33. Konduri SD, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 2001, 20(47):6938-45. 10.1038/sj.onc.1204847, 11687973.
34. Tang Z, et al. Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis. Med Oncol 2009,